The contacts were designed by researchers at the Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology, Boston Children’s Hospital, and the Massachusetts Institute of Technology with materials that are FDA-approved for use on the eye.
‘In general, eye drops are an inefficient method of drug delivery that has notoriously poor patient adherence. This contact lens design can potentially be used as a treatment for glaucoma and as a platform for other ocular drug delivery applications,’ said Joseph Ciolino, M.D, Mass. Eye and Ear cornea specialist and lead author of the paper.
The latanoprost-eluting contact lenses were created by encapsulating latanoprost-polymer films in commonly used contact lens hydrogel. Their findings are described online and will be in the January 2014 printed issue of Biomaterials.
‘The lens we have developed is capable of delivering large amounts of drug at substantially constant rates over weeks to months,’ said Prof Daniel Kohane, director of the Laboratory for Biomaterials and Drug Delivery at Boston Children’s Hospital.
According to a statement, in vivo, single contact lenses were able to achieve, for one month, latanoprost concentrations in the aqueous humour that were comparable to those achieved with daily topical latanoprost solution, the current first-line treatment for glaucoma.
The lenses appeared safe in cell culture and animal studies and this is the first contact lens that has been shown to release drugs for this long in animal models.
The newly designed contact lens has a clear central aperture and contains a drug-polymer film in the periphery, which helps to control drug release. The lenses can be made with no refractive power or with the ability to correct the refractive error in near sided or far sided eyes.
‘A non-invasive method of sustained ocular drug delivery could help patients adhere to the therapy necessary to maintain vision in diseases like glaucoma, saving millions from preventable blindness,’ Dr. Ciolino said.